NATERA INC

NASDAQ: NTRA (Natera, Inc.)

Last update: 10 hours ago

319.09

-3.85 (-1.19%)

Previous Close 322.94
Volume 1,690,805
Price / Earnings (Forward) 5.05
Price / Sales 15.56
Price / Book 24.64
52 Weeks Range
181.00 (-43%) — 437.41 (37%)
Profit Margin -10.36%
Operating Margin (TTM) -15.78%
Diluted EPS (TTM) -1.47
Quarterly Revenue Growth (YOY) 36.50%
Total Debt/Equity (MRQ) 15.78%
Current Ratio (MRQ) 3.87
Operating Cash Flow (TTM) 153.12 M
Levered Free Cash Flow (TTM) 120.93 M
Return on Assets (TTM) -8.87%
Return on Equity (TTM) -18.66%

AIStockmoo Score

0.5
Value 30% 0.0
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Low debt. Weak profitability. Ample short-term liquidity. Positive cash flow. info
Return on Capital info NA
Timing 30% 0.4
From our AI technical analysis of the chart. info NA
Uptrend over the past year. Far below its 52-week high. info
Recent bullish reversal pattern: Bullish engulfing. info
Trend for Your Holding Period info NA
Sentiment 20% 0.2
No recent price targets, so based on how targets have been revised. info
Recent news mixed or neutral. info
Smart Money 20% 1.6
No clear net insider buying or selling. info
Institutions net +5.08% of shares in their latest 13F filings: 573 holders increased, 379 decreased (quarter to 30 Sep 2026). info
Short interest +10.1% from 31 Aug to 30 Oct 2026, 4.2 days to cover (FINRA). info
Market and sector conditions are favourable.
Market environment cautious. info
Sector outperforming the market.
Only one pillar has a clear reading, so the score is unchanged.
Not in score
Price is high against its 52-week average. Up over 5 years. info
Short-term momentum falling. info
Price is near support. info
Final Score 0.51

Market Trend

Short Term Medium Term
Industry Diagnostics & Research (US) Mixed Bullish
Diagnostics & Research (Global) Mixed Bullish
Stock Natera, Inc. Mixed Bullish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
NTRA - - - 24.64
ILMN - - - 10.39
IDXX - - - 29.71
MEDP - - - 31.78
GH - - - -
BLLN - - - 8.84

Select this tab to load the latest available analysis.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Sector Healthcare
Industry Diagnostics & Research
Investment Style Mid Growth
% Held by Insiders 3.24%
% Held by Institutions 96.37%

Ownership

Name Date Shares Held
Castle Hook Partners Lp 30 Jun 2026 2,596,276
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
BROPHY MICHAEL BURKES - 384.66 -795 -305,805
CHAPMAN STEVEN LEONARD - 378.92 -3,801 -1,440,275
FESKO JOHN - 378.92 -302 -114,434
MOSHKEVICH SOLOMON - 378.92 -3,419 -1,295,527
RABINOWITZ DANIEL - 378.92 -341 -129,212
RABINOWITZ MATTHEW - 378.92 -748 -283,432
SHEENA JONATHAN - 313.01 -3,262 -1,021,050
Aggregate Net Quantity -12,668
Aggregate Net Value ($) -4,589,735
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 362.31
Name Holder Date Type Quantity Price Value ($)
SHEENA JONATHAN Director 06 Nov 2026 Automatic sell (-) 3,150 310.67 978,611
BROPHY MICHAEL BURKES Officer 03 Nov 2026 Automatic sell (-) 470 388.63 182,656
FESKO JOHN Officer 02 Nov 2026 Automatic sell (-) 302 378.92 114,434
BROPHY MICHAEL BURKES Officer 02 Nov 2026 Automatic sell (-) 325 378.92 123,149
RABINOWITZ DANIEL Officer 02 Nov 2026 Automatic sell (-) 341 378.92 129,212
MOSHKEVICH SOLOMON Officer 02 Nov 2026 Automatic sell (-) 3,419 378.92 1,295,527
CHAPMAN STEVEN LEONARD Officer 02 Nov 2026 Automatic sell (-) 3,801 378.92 1,440,275
SHEENA JONATHAN Director 02 Nov 2026 Automatic sell (-) 112 378.92 42,439
RABINOWITZ MATTHEW Officer 02 Nov 2026 Automatic sell (-) 748 378.92 283,432

Institutions

Institutional ownership: 109.18%

Positions Holders Shares
Increased 573 19,172,679
Decreased 379 13,062,416
New 192 1,811,976
Sold out 81 559,254

SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.

Short Interest

Settlement Shares Days to cover
30 Oct 2026 6,072,554 4.2
15 Oct 2026 5,851,917 3.4
30 Sep 2026 6,355,450 3.2
15 Sep 2026 4,797,175 4.7
31 Aug 2026 5,514,178 4.4
14 Aug 2026 4,295,245 2.6

FINRA short interest via Nasdaq, reported twice a month.

9 Positive 6 Negative 6 Neutral
Date Type Details
15 Nov 2026 Yahoo Finance Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029
Natera (NASDAQ:NTRA) Chief Financial Officer Mike Brophy said the company has multiple paths to its $6 billion revenue target for 2029, citing growth in its Signatera cancer testing business and opportunities to improve reimbursement. Speaking at a UBS event, Brophy also addressed Natera’s CEO tran…
14 Nov 2026 Yahoo Finance Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”
Natera (NASDAQ:NTRA) CFO Mike Brophy said the company’s newly announced $6 billion revenue target for 2029 is achievable with strong execution, as he outlined expectations for its Signatera cancer test and defended the immediate transition to a new CEO. Speaking at a Wolfe Research event, Brophy sa…
13 Nov 2026 Yahoo Finance Is Natera (NTRA) Still Cheap, Or Is Cash Flow Doing The Heavy Lifting?
Natera has delivered very large share gains over the past three years, yet recent share price swings and shifting expectations now put the focus squarely on whether the current valuation lines up with the cash the business is expected to generate. With investors digesting new clinical data…
13 Nov 2026 Yahoo Finance ETFs Are Net Sellers of Natera (NTRA) on Wednesday
ETFs sold $13.0 million of Natera (NTRA) in Wednesday's session.
13 Nov 2026 Yahoo Finance How Incyte Trial And New Cancer Data Will Impact Natera Stock
Natera announced several updates in early November 2026, including new Signatera clinical data across multiple tumor types and a fresh collaboration with Incyte on a Phase II colorectal cancer study that uses Signatera as both a primary and secondary endpoint. The new colorectal cancer trial…
12 Nov 2026 Yahoo Finance Natera (NTRA) Following Clinical Momentum Looks Fully Valued To Some
Clinical momentum puts Natera in focus Natera (NTRA) is back on traders’ screens after fresh clinical momentum. A new colorectal cancer trial with Incyte centers on the Signatera minimal residual disease test as both a primary and a secondary endpoint. Natera’s recent clinical updates arrive after…
11 Nov 2026 Yahoo Finance The Fund Exited Natera (NTRA) on Valuation Concerns Despite Strong Fundamentals
Baron Capital, an investment management company, released its third-quarter 2026 investor letter for its “Baron SMID Cap ETF”. The letter can be downloaded here. The Baron SMID Cap ETF showed a solid rebound in Q3, declining 2.87% (NAV) compared to a 10.35% drop in the Russell 2500 Growth Index.…
11 Nov 2026 Yahoo Finance Carrier Screening - Global Strategic Business Report 2026: Secure Your Share of a $7.6 Billion Market by 2032 | Features Competitive Intelligence on Illumina, Natera, BGI Genomics, and Myriad Genetics
NGS, AI, at-home testing and universal screening are expanding access, accuracy and test breadth, creating opportunities in personalized reproductive careDublin, Nov. 11, 2026 (GLOBE NEWSWIRE) -- "Carrier Screening - Global Strategic Business Report" has been added to ResearchAndMarkets.com's…
11 Nov 2026 Yahoo Finance Strong Q2 Results and Raised Revenue Guidance Drive Natera’s (NTRA)Outperformance
Carillon Tower Advisers, an investment management company, released its third-quarter 2026 investor letter for the “Carillon Eagle Mid Cap Growth Fund”. The letter can be downloaded here. Mid-cap stocks pulled back in the third quarter of 2026 as the Russell Midcap Growth Index fell 5.84%…
11 Nov 2026 Yahoo Finance Natera and Incyte partner on Phase II colorectal cancer trial
The trial focuses on individuals with stage 2/3 colorectal cancer who have completed surgical resection and adjuvant chemotherapy.
10 Nov 2026 Yahoo Finance Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
AUSTIN, Texas, November 10, 2026--Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) for a new phase II study in colorectal cancer (CRC).
09 Nov 2026 Yahoo Finance Natera Q3 Earnings Call Highlights $6B Target & Raised 2026 Outlook
NTRA targets $6B in revenues by 2029 as Signatera testing surges, reimbursement expands and higher investments support its long-term growth strategy.
09 Nov 2026 Yahoo Finance NTRA Q3 2026 deep dive: management transition and pharma business investments offset margin gains
Genetic testing company Natera (NASDAQ:NTRA) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 34.1% year on year to $794 million. The company’s full-year revenue guidance of $3.02 billion at the midpoint came in 3.8% above analysts’ estimates. Its GAAP loss of…
07 Nov 2026 Yahoo Finance Natera (NTRA) Hands CEO Role To Longtime Insider As New Cancer Data Lands
Natera (NasdaqGS:NTRA) appointed long-time executive Solomon Moshkevich as chief executive officer, following 15 years with the company. The management change accompanies new peer-reviewed data on Natera's Signatera test across multiple cancer indications. Recent clinical publications and…
06 Nov 2026 Yahoo Finance It Was Already A Gory Day For Blood-Testing Stocks — Then, Natera And Guardant Reported
Guardant Health stock and Natera stock extended their Thursday losses on Friday though the duo beat third-quarter sales views.
06 Nov 2026 Yahoo Finance Natera Sinks 14% as CEO Steve Chapman Steps Down Despite Q3 Beat: “An Excellent Time to Transition”
Key TakeawaysNatera fell 14% despite a third-quarter beat and a $140 million guidance raise, as Steve Chapman handed the CEO job to Solomon Moshkevich. The loss was wider than expected, and spending plans rose too.
06 Nov 2026 Yahoo Finance Natera (NTRA) Q3 2026 Earnings Call Transcript
Natera's new CEO outlines a path to double revenue by 2029…
06 Nov 2026 Yahoo Finance Natera Stocks Slide 15.07% After Wider Loss and Sudden CEO Change
Revenue jumped 34% and guidance rose, but Steve Chapman stepped down as CEO effective immediately.
06 Nov 2026 Yahoo Finance Natera promotes Solomon Moshkevich to CEO
The CEO change was unexpected and prompted a stock selloff Friday, analysts said, but the new chief executive is prepared for the role.
06 Nov 2026 Yahoo Finance Update: Natera Shares Fall After Wider-Than-Expected Q3 Loss
(Updates with the latest stock price movement in the headline and the first paragraph.) Natera (N…
06 Nov 2026 Yahoo Finance Natera Q3 Results, 2029 Revenue Target Support Growth Outlook, RBC Says
Natera (NTRA) reported better-than-expected Q3 revenue and raised its 2026 guidance, reinforcing its…
Show more

Recent Signals candle patterns and EMA crosses

▲ Bullish engulfing 1 session ago · 12 Nov
An up candle whose body fully covers the previous down candle, after a decline. A bullish reversal signal.
▼ Bearish EMA cross 1 session ago · 12 Nov
Medium term · EMA 20/50
The 20-day EMA crossed below the 50-day: the medium-term trend turned down.

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria